PCR London Valves 2024

25 Nov 2024

TAVI

New frontiers in TAVI: have we reached them?

Sponsored by Edwards Lifesciences

Anchorperson: V. Delgado

Discussants: H. Eltchaninoff, P. Genereux, J. Mascherbauer, P. Pibarot, H. Treede, M. Nicotera

SHOW MORE

Summary

Discover the latest advancements in TAVI as we look into the results of the EARLY TAVR and RHEIA trials. Explore how these groundbreaking findings may influence clinical practice guidelines and shape the future of TAVI, as well as the remaining unmet clinical needs in TAVI.

Learning Objectives

To discover the results of the latest randomised clinical trials in TAVI: EARLY TAVR and RHEIA
To learn how these new data may impact clinical practice guidelines
To discuss what will be the new frontiers in TAVI including the treatment of patients with bicuspid aortic valve and moderate aortic stenosis

Speaker

Welcome and session objectives

Download presentation

Philippe Genereux

Speaker

EARLY TAVR: what you need to know

Download presentation

Speaker

How will the EARLY TAVR findings impact on clinical guidelines?

Download presentation

Speaker

J. Mascherbauer

New frontiers in asymptomatic patients: case examples

Download presentation

Speaker

H. Eltchaninoff

RHEIA: what you need to know

Download presentation

Speaker

How will the RHEIA findings impact on clinical guidelines?

Download presentation

Speaker

New frontiers in female patients: case examples

Download presentation

Speaker

What are the unmet clinical needs in TAVI?

Download presentation